These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 24900853)
1. 3-Amido-3-aryl-piperidines: A Novel Class of Potent, Selective, and Orally Active GlyT1 Inhibitors. Pinard E; Alberati D; Alvarez-Sanchez R; Brom V; Burner S; Fischer H; Hauser N; Kolczewski S; Lengyel J; Mory R; Saladin C; Schulz-Gasch T; Stalder H ACS Med Chem Lett; 2014 Apr; 5(4):428-33. PubMed ID: 24900853 [TBL] [Abstract][Full Text] [Related]
2. Discovery of N-(2-aryl-cyclohexyl) substituted spiropiperidines as a novel class of GlyT1 inhibitors. Pinard E; Ceccarelli SM; Stalder H; Alberati D Bioorg Med Chem Lett; 2006 Jan; 16(2):349-53. PubMed ID: 16246557 [TBL] [Abstract][Full Text] [Related]
3. Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. Pinard E; Alberati D; Borroni E; Fischer H; Hainzl D; Jolidon S; Moreau JL; Narquizian R; Nettekoven M; Norcross RD; Stalder H; Thomas AW Bioorg Med Chem Lett; 2008 Sep; 18(18):5134-9. PubMed ID: 18752953 [TBL] [Abstract][Full Text] [Related]
4. 4-Substituted-8-(1-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with superior pharmacological and pharmacokinetic parameters. Alberati D; Hainzl D; Jolidon S; Kurt A; Pinard E; Thomas AW; Zimmerli D Bioorg Med Chem Lett; 2006 Aug; 16(16):4321-5. PubMed ID: 16762550 [TBL] [Abstract][Full Text] [Related]
5. Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors. Pinard E; Alberati D; Bender M; Borroni E; Brom V; Burner S; Fischer H; Hainzl D; Halm R; Hauser N; Jolidon S; Lengyel J; Marty HP; Meyer T; Moreau JL; Mory R; Narquizian R; Norcross RD; Schmid P; Wermuth R; Zimmerli D Bioorg Med Chem Lett; 2010 Dec; 20(23):6960-5. PubMed ID: 20974532 [TBL] [Abstract][Full Text] [Related]
6. Novel GlyT1 inhibitor chemotypes by scaffold hopping. Part 1: development of a potent and CNS penetrant [3.1.0]-based lead. Jones CK; Sheffler DJ; Williams R; Jadhav SB; Felts AS; Morrison RD; Niswender CM; Daniels JS; Conn PJ; Lindsley CW Bioorg Med Chem Lett; 2014 Feb; 24(4):1067-70. PubMed ID: 24461352 [TBL] [Abstract][Full Text] [Related]
7. Oleoyl-L-carnitine inhibits glycine transport by GlyT2. Carland JE; Mansfield RE; Ryan RM; Vandenberg RJ Br J Pharmacol; 2013 Feb; 168(4):891-902. PubMed ID: 22978602 [TBL] [Abstract][Full Text] [Related]
8. Identification of an Orally Bioavailable, Potent, and Selective Inhibitor of GlyT1. Blackaby WP; Lewis RT; Thomson JL; Jennings AS; Goodacre SC; Street LJ; MacLeod AM; Pike A; Wood S; Thomas S; Brown TA; Smith A; Pillai G; Almond S; Guscott MR; Burns HD; Eng W; Ryan C; Cook J; Hamill TG ACS Med Chem Lett; 2010 Oct; 1(7):350-4. PubMed ID: 24900218 [TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-substituted-8-(2-hydroxy-2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of highly selective GlyT1 inhibitors with improved metabolic stability. Alberati D; Hainzl D; Jolidon S; Krafft EA; Kurt A; Maier A; Pinard E; Thomas AW; Zimmerli D Bioorg Med Chem Lett; 2006 Aug; 16(16):4311-5. PubMed ID: 16757170 [TBL] [Abstract][Full Text] [Related]
10. Inhibitors of farnesyl protein transferase. 4-Amido, 4-carbamoyl, and 4-carboxamido derivatives of 1-(8-chloro-6,11-dihydro-5H-benzo[5,6]- cyclohepta[1,2-b]pyridin-11-yl)piperazine and 1-(3-bromo-8-chloro-6,11- dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperazine. Mallams AK; Rossman RR; Doll RJ; Girijavallabhan VM; Ganguly AK; Petrin J; Wang L; Patton R; Bishop WR; Carr DM; Kirschmeier P; Catino JJ; Bryant MS; Chen KJ; Korfmacher WA; Nardo C; Wang S; Nomeir AA; Lin CC; Li Z; Chen J; Lee S; Dell J; Lipari P; Liu M J Med Chem; 1998 Mar; 41(6):877-93. PubMed ID: 9526562 [TBL] [Abstract][Full Text] [Related]
11. Inhibitors of GlyT1 affect glycine transport via discrete binding sites. Mezler M; Hornberger W; Mueller R; Schmidt M; Amberg W; Braje W; Ochse M; Schoemaker H; Behl B Mol Pharmacol; 2008 Dec; 74(6):1705-15. PubMed ID: 18815213 [TBL] [Abstract][Full Text] [Related]
12. Selective, orally active MMP inhibitors with an aryl backbone. Barta TE; Becker DP; Bedell LJ; De Crescenzo GA; McDonald JJ; Mehta P; Munie GE; Villamil CI Bioorg Med Chem Lett; 2001 Sep; 11(18):2481-3. PubMed ID: 11549451 [TBL] [Abstract][Full Text] [Related]
13. Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors. Vacher B; Bonnaud B; Funes P; Jubault N; Koek W; Assié MB; Cosi C; Kleven M J Med Chem; 1999 May; 42(9):1648-60. PubMed ID: 10229633 [TBL] [Abstract][Full Text] [Related]
14. Lipid inhibitors of high affinity glycine transporters: identification of a novel class of analgesics. Carland JE; Handford CA; Ryan RM; Vandenberg RJ Neurochem Int; 2014 Jul; 73():211-6. PubMed ID: 24036283 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of 4-substituted-8-(2-phenyl-cyclohexyl)-2,8-diaza-spiro[4.5]decan-1-one as a novel class of GlyT1 inhibitors: achieving selectivity against the mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors. Alberati D; Ceccarelli SM; Jolidon S; Krafft EA; Kurt A; Maier A; Pinard E; Stalder H; Studer D; Thomas AW; Zimmerli D Bioorg Med Chem Lett; 2006 Aug; 16(16):4305-10. PubMed ID: 16762548 [TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel class of zwitterionic, potent, selective and orally active S1P₁ direct agonists. Aguilar N; Mir M; Grima PM; López M; Segarra V; Esteban L; Moreno I; Godessart N; Tarrasón G; Domenech T; Vilella D; Armengol C; Córdoba M; Sabaté M; Casals D; Domínguez M Bioorg Med Chem Lett; 2012 Dec; 22(24):7672-6. PubMed ID: 23141913 [TBL] [Abstract][Full Text] [Related]
17. Discovery and SAR studies of novel GlyT1 inhibitors. Walter MW; Hoffman BJ; Gordon K; Johnson K; Love P; Jones M; Man T; Phebus L; Reel JK; Rudyk HC; Shannon H; Svensson K; Yu H; Valli MJ; Porter WJ Bioorg Med Chem Lett; 2007 Sep; 17(18):5233-8. PubMed ID: 17629697 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and SAR of GlyT1 inhibitors derived from a series of N-((4-(morpholine-4-carbonyl)-1-(propylsulfonyl)piperidin-4-yl)methyl)benzamides. Zhao Z; O'Brien JA; Lemaire W; Williams DL; Jacobson MA; Sur C; Pettibone DJ; Tiller PR; Smith S; Hartman GD; Wolkenberg SE; Lindsley CW Bioorg Med Chem Lett; 2006 Dec; 16(23):5968-72. PubMed ID: 16987662 [TBL] [Abstract][Full Text] [Related]
19. Novel 3-Oxazolidinedione-6-aryl-pyridinones as Potent, Selective, and Orally Active EP3 Receptor Antagonists. Jin J; Morales-Ramos A; Eidam P; Mecom J; Li Y; Brooks C; Hilfiker M; Zhang D; Wang N; Shi D; Tseng PS; Wheless K; Budzik B; Evans K; Jaworski JP; Jugus J; Leon L; Wu C; Pullen M; Karamshi B; Rao P; Ward E; Laping N; Evans C; Leach C; Holt D; Su X; Morrow D; Fries H; Thorneloe K; Edwards R ACS Med Chem Lett; 2010 Oct; 1(7):316-20. PubMed ID: 24900213 [TBL] [Abstract][Full Text] [Related]
20. A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease. Harada K; Nakato K; Yarimizu J; Yamazaki M; Morita M; Takahashi S; Aota M; Saita K; Doihara H; Sato Y; Yamaji T; Ni K; Matsuoka N Eur J Pharmacol; 2012 Jun; 685(1-3):59-69. PubMed ID: 22542656 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]